Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Targovax protects its neoantigen vaccines in USA for RAS-mutated cancers
September 25, 2017 Off

Targovax protects its neoantigen vaccines in USA for RAS-mutated cancers

By Dino Mustafić

Targovax has obtained the patent from the US Patent and Trademark Office for it’s mutant-RAS specific neoantigen vaccines, TG01 and…

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
September 22, 2017 Off

Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries

By Dino Mustafić

Novartis has enterned in new collaboration with The Max Foundation to support continued access to treatment at no cost for nearly 34,000 current patients with chronic myeloid leukemia (CML), gastrointestinal tumors (GIST) and other rare cancers.

Sanofi, Alnylam’s ATTR amyloidosis study meets main goal
September 21, 2017 Off

Sanofi, Alnylam’s ATTR amyloidosis study meets main goal

By Dino Mustafić

Sanofi’s speciality care unit Genzyme together with an RNAi therapeutics company Alnylam Pharmaceuticals, announced Wednesday that the APOLLO Phase 3…

EC approves Novartis’s cancer drug for 2 indications
September 20, 2017 Off

EC approves Novartis’s cancer drug for 2 indications

By Dino Mustafić

The European Commission has approved Novartis’s Rydapt for two indications in rare cancers, in combination with standard daunorubicin and cytarabine…

Alkermes gets good results testing Aristada for schizophrenia
September 19, 2017 Off

Alkermes gets good results testing Aristada for schizophrenia

By Dino Mustafić

Alkermes revealed positive results from a phase 4 clinical study of its schizophrenia injectable drug Aristada. Alkermes said on Monday…

Allergy Therapeutics wins approval for PQ Grass phase II trial
September 18, 2017 Off

Allergy Therapeutics wins approval for PQ Grass phase II trial

By Dino Mustafić

Allergy Therapeutics, a pharmaceutical group specialising in allergy vaccines, has announced that the fully-funded Phase II clinical trial investigating the dosing of PQ Grass has received clinical trial application (CTA) approval.

EMA’s CHMP says No to Santhera’s Raxone in DMD, appeal on the way
September 15, 2017 Off

EMA’s CHMP says No to Santhera’s Raxone in DMD, appeal on the way

By Dino Mustafić

Santhera Pharmaceuticals said on Friday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…

Nordic Star Awards was presented at the NLSDays conference
September 15, 2017 Off

Nordic Star Awards was presented at the NLSDays conference

By Dino Mustafić

Herantis Pharma, Targovax, Pelago get the Nordic Stars Award at the Nordic Life Sciences Days in Malmö, Sweden. Nordic Stars…

Novartis’s adalimumab offers alternative for patients with immunological diseases
September 14, 2017 Off

Novartis’s adalimumab offers alternative for patients with immunological diseases

By Dino Mustafić

Sandoz, a Novartis division has reported new data on its proposed biosimilar adalimumab.

Biocartis, Genomic Health bring together their Oncotype DX breast recurrence score test and Idylla platform
September 13, 2017 Off

Biocartis, Genomic Health bring together their Oncotype DX breast recurrence score test and Idylla platform

By Dino Mustafić

Biocartis and Genomic Health have entered a deal to develop an IVD version of the Oncotype DX Breast Recurrence Score…

Posts pagination

Previous 1 … 3,434 3,435 3,436 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine